Advance on immunotherapy and prognosis of Guillain-Barré syndrome
10.3760/cma.j.issn.2095-428X.2019.24.018
- VernacularTitle: 吉兰－巴雷综合征免疫治疗及预后评估研究进展
- Author:
Hanyu LUO
1
,
2
;
Li JIANG
Author Information
1. Department of Neurology, Children′s Hospital of Chongqing Medical University
2. Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing 400014, China
- Publication Type:Review
- Keywords:
Guillain-Barré syndrome;
Complement inhibitor;
Albumin;
Prognosis
- From:
Chinese Journal of Applied Clinical Pediatrics
2019;34(24):1907-1910
- CountryChina
- Language:Chinese
-
Abstract:
Guillain-Barré syndrome (GBS) is an acute onset immune-mediated polyradiculoneuropathy, and it is the most frequent cause of acute flaccid paralysis.Intravenous immunoglobulin and plasma exchange are proved to be an effective treatment.Despite the efficacy of immunotherapy, a significant number of patients have a poor prognosis, leaving behind severe dysfunction and even death.Therefore, biomarkers and prognostic models are needed to accurately predict outcome, which could help the early recognition of patients with poor outcomes, which may potentially be-nefit from individualized treatments.So, new development of immunotherapy and prognostic evaluation of GBS were summarized in this paper, in order to provide the evidence for clinical diagnosis and treatment.
